Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

Theranexus September 30th cash position and business update
Download PDF File (369 Ko)

Theranexus announces inclusion of last patient in phase II trial of drug candidate THN102 on narcolepsy patients

Download PDF File (371 Ko)

Theranexus plans to extend its phase 2 pipeline with a third program

Download PDF File (382 Ko)

Theranexus announces that Rodolphe Besserve will join its Board of Directors

Download PDF File (368 Ko)

Theranexus announces a new European patent protecting THN201, its drug candidate for the treatment of neurocognitive disorders including those associated with Alzheimers

Download PDF File (373 Ko)

 Recognition of the scientific excellence of Theranexus

Download PDF File (379 Ko)

Theranexus announces its first half 2018 results

Download PDF File (335 Ko)

Theranexus obtains the authorization to start a Phase 1b clinical trial with its drug candidate THN201 in neurocognitive disorders due to Alzheimer's disease

Download PDF file (384 Ko)

Theranexus announces the inclusion of the first patient in its phase 2 clinical trial evaluating its drug candidate THN102 in excessive daytime sleepiness (EDS) in patients with Parkinson's disease

Download the PDF file (397 Ko)

Theranexus presents new data on the stimulating effect of its drug candidate THN 102

Download PDF file (306 Ko)